Sjogren's Syndrome

Autoimmune MONDO:0010030 Pathograph 2 Autoimmune Disease

A rare systemic autoimmune disease characterized by exocrine gland dysfunction, resulting predominately in keratoconjunctivitis sicca and xerostomia, but also affecting exocrine glands of the skin, as well as respiratory, urogenital, and digestive tract. Extraglandular manifestations include arthritis, interstitial lung disease, renal disease, and peripheral neuropathy. The disease is accompanied by a substantially increased risk to develop B-cell non-Hodgkin lymphoma, especially MALT lymphoma.

Ask OpenScientist

Ask a research question about Sjogren's Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

0
Mappings
0
Definitions
0
Inheritance
6
Pathophysiology
0
Histopathology
14
Phenotypes
2
Pathograph
4
Genes
5
Treatments
0
Subtypes
0
Differentials
0
Datasets
0
Trials
0
Models
7
References
2
Deep Research
🏷

Classifications

Harrison's Chapter
musculoskeletal system disorder connective tissue disease autoimmune disease
⚙

Pathophysiology

6
Exocrine Gland Lymphocytic Infiltration
CD4+ T cells and B cells infiltrate salivary and lacrimal glands, forming ectopic germinal center-like structures. This lymphocytic infiltration leads to progressive glandular destruction and dysfunction.
CD4+ T Cell link B Cell link
Adaptive Immune Response link
Show evidence (2 references)
PMID:33911236 SUPPORT
"The ductal cells of the salivary gland in pSS are characteristically surrounded by a CD4+ T cell-rich and B cell-rich infiltrate, implying a degree of communication between epithelial cells and immune cells."
Demonstrates the characteristic lymphocytic infiltration pattern in salivary glands with both CD4+ T cells and B cells surrounding ductal epithelium.
ORPHA:289390 SUPPORT Other
"A rare systemic autoimmune disease characterized by exocrine gland dysfunction"
Orphanet definition confirms exocrine gland dysfunction as the hallmark of primary Sjogren disease.
Autoantibody Production
Characteristic autoantibodies include anti-Ro/SSA and anti-La/SSB, which target ribonucleoprotein complexes. These antibodies serve as diagnostic markers and may contribute to tissue damage through immune complex formation.
Immunoglobulin Production link
Show evidence (2 references)
PMID:38542233 PARTIAL
"Primary Sjögren's disease is primarily driven by B-cell activation and is associated with a high risk of developing non-Hodgkin's lymphoma (NHL)."
Highlights the central role of B-cell activation in primary Sjögren's disease, which drives autoantibody production including anti-Ro/SSA and anti-La/SSB antibodies.
PMID:28735431 SUPPORT Human Clinical
"There was a significant variation of positive serological markers, with anti-Ro antibodies reported between 15.7-75.0% and 36.4-84.6%, and anti-La antibodies between 5.6-51.7% and 27.3-65.4%, in the male and paediatric populations, respectively."
Systematic review providing prevalence ranges for anti-Ro and anti-La antibody positivity across different populations.
Type I Interferon Signature
Elevated type I interferon activity drives disease pathogenesis through activation of plasmacytoid dendritic cells and upregulation of interferon-stimulated genes in affected tissues.
Type I Interferon Response link
Show evidence (2 references)
PMID:33911236 PARTIAL
"Multiple innate immune pathways are likely dysregulated in the salivary gland epithelium in pSS, including the nuclear factor-κB pathway, the inflammasome and interferon signalling."
Confirms that interferon signaling is a key dysregulated pathway in the salivary gland epithelium, contributing to the type I interferon signature observed in Sjogren syndrome.
PMID:38982205 PARTIAL
"Several randomized controlled trials have just been completed or are poised to commence evaluating the effectiveness of novel drugs targeting both innate and adaptive immune pathways, including pro-inflammatory cytokines, the type I interferon system, B cell activation, B cell and T cell..."
Highlights type I interferon system as a major therapeutic target in Sjogren syndrome, underscoring its central pathogenic role.
Epithelial Cell Dysfunction
Salivary and lacrimal gland epithelial cells exhibit intrinsic abnormalities including aberrant apoptosis, antigen presentation via MHC class II, and production of pro-inflammatory cytokines including BAFF.
Epithelial Cell link
Apoptotic Process link
Show evidence (2 references)
PMID:33911236 PARTIAL
"B cell infiltrates within the ducts can initiate the development of lymphoepithelial lesions, including basal ductal cell hyperplasia. Vice versa, the epithelium provides chronic activation signals to the glandular B cell fraction."
Demonstrates that epithelial cells actively participate in disease pathogenesis by providing chronic activation signals to immune cells, not merely serving as passive targets.
PMID:38982205 PARTIAL
"Sjögren syndrome or Sjögren disease is a chronic form of autoimmune epithelitis characterized by lymphocytic infiltration of the exocrine glands, particularly the salivary and lacrimal glands, leading to progressive glandular dysfunction and subsequent xerostomia and xerophthalmia."
Defines the disease as an autoimmune epithelitis, emphasizing the central role of epithelial cell dysfunction in disease pathology and clinical manifestations.
Salivary Gland JAK-STAT Activation and ISG Upregulation
Salivary gland epithelial cells and immune cells in Sjögren's disease exhibit cell type-specific upregulation of interferon-stimulated genes (ISGs) and aberrant activation of the JAK-STAT signaling pathway, correlating with clinical severity indicators including focus score and anti-SSA seropositivity. JAK inhibition normalises this signalling, establishing the IFN-JAK-STAT axis as a primary pathogenic driver and therapeutic target.
Salivary Gland Epithelial Cell link
JAK-STAT Signaling Cascade link
Show evidence (1 reference)
PMID:38527764 SUPPORT Human Clinical
"SjD patients' tissues exhibit increased expression of ISGs and activation of the JAK-STAT pathway in a cell type-dependent manner. JAKi normalises this aberrant signalling at the tissue level and in PBMCs, suggesting a putative viable therapy for SjD, targeting both glandular and extraglandular symptoms."
Human tissue study demonstrating cell type-specific JAK-STAT pathway activation and ISG upregulation in Sjögren's disease salivary glands, with JAK inhibition normalising aberrant signalling and prompting a tofacitinib clinical trial.
B-cell Lymphomagenesis
Chronic B-cell activation and ectopic germinal center formation in salivary glands create a microenvironment that promotes clonal B-cell expansion and progression to mucosa-associated lymphoid tissue (MALT) lymphoma. This represents the most serious complication of the disease.
B Cell link
B Cell Proliferation link
Downstream
Non-Hodgkin Lymphoma Risk
Show evidence (3 references)
PMID:38542233 SUPPORT
"miR-155 expression correlated with the focus score (FS), as well as BAFF-R and IL-6R expression, which were increased in primary Sjögren's disease patients and in turn related to neoplastic evolution."
Demonstrates that B-cell activation biomarkers in salivary glands correlate with lymphomagenesis risk in primary Sjogren disease.
PMID:33911236 SUPPORT
"This continuous stimulation might ultimately drive the development of mucosa-associated lymphoid tissue lymphoma."
Describes how chronic epithelial-immune stimulation drives MALT lymphoma development.
ORPHA:289390 SUPPORT Other
"accompanied by a substantially increased risk to develop B-cell non-Hodgkin lymphoma, especially MALT (mucosa-associated lymphoid tissue) lymphoma"
Orphanet definition confirms the substantially increased lymphoma risk in primary Sjogren disease.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Sjogren's Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

14
Cardiovascular 3
Keratoconjunctivitis Sicca VERY_FREQUENT Keratoconjunctivitis sicca (HP:0001097)
Dry eyes are a cardinal feature of the disease, present in the majority of patients.
Show evidence (2 references)
ORPHA:289390 SUPPORT Other
"resulting predominately in keratoconjunctivitis sicca and xerostomia"
Orphanet definition lists keratoconjunctivitis sicca as a predominant manifestation.
PMID:37068269 SUPPORT Human Clinical
"Women with pSS demonstrated a higher prevalence of dry mouth, dry eyes, arthralgia, and dental caries"
Large cohort study confirming high prevalence of dry eyes in pSS.
Lymphadenopathy OCCASIONAL Lymphadenopathy (HP:0002716)
May be generalized or regional; requires evaluation to exclude lymphoma.
Show evidence (1 reference)
PMID:28735431 SUPPORT Human Clinical
"children diagnosed with pSS reported less dryness and had a higher prevalence of parotitis, lymphadenopathy and systemic symptoms"
Systematic review documenting lymphadenopathy as a manifestation of pSS, particularly prominent in pediatric populations.
Raynaud Phenomenon OCCASIONAL Raynaud phenomenon (HP:0030880)
Vasospastic episodes of the digits; associated with more severe systemic disease.
Show evidence (1 reference)
PMID:16996579 SUPPORT Human Clinical
"the main diagnostic problems occur in SS patients presenting with arthritis, Raynaud phenomenon, cutaneous features (subacute cutaneous lupus erythematosus, purpura, livedo reticularis, erythema nodosum), interstitial pulmonary disease, and cytopenias (leukopenia, thrombocytopenia)."
Review of extraglandular manifestations identifies Raynaud phenomenon as a major clinical feature in primary Sjögren's syndrome.
Head and Neck 2
Xerostomia VERY_FREQUENT Xerostomia (HP:0000217)
Dry mouth due to salivary gland dysfunction; a cardinal feature of the disease.
Show evidence (3 references)
PMID:38982205 SUPPORT
"Sjögren syndrome or Sjögren disease is a chronic form of autoimmune epithelitis characterized by lymphocytic infiltration of the exocrine glands, particularly the salivary and lacrimal glands, leading to progressive glandular dysfunction and subsequent xerostomia and xerophthalmia."
Xerostomia is listed as a primary clinical manifestation resulting from progressive salivary gland dysfunction.
ORPHA:289390 SUPPORT Other
"resulting predominately in keratoconjunctivitis sicca and xerostomia"
Orphanet definition lists xerostomia as a predominant manifestation.
PMID:37068269 SUPPORT Human Clinical
"Women with pSS demonstrated a higher prevalence of dry mouth, dry eyes, arthralgia, and dental caries"
Large cohort study confirming high prevalence of dry mouth in pSS patients.
Dental Caries FREQUENT Carious teeth (HP:0000670)
Accelerated dental decay secondary to reduced salivary flow.
Show evidence (1 reference)
PMID:37068269 SUPPORT Human Clinical
"Women with pSS demonstrated a higher prevalence of dry mouth, dry eyes, arthralgia, and dental caries"
Large cohort study documenting dental caries as a significant complication in pSS.
Musculoskeletal 1
Arthritis FREQUENT Arthritis (HP:0001369)
Non-erosive polyarthritis, predominantly affecting small joints.
Show evidence (1 reference)
ORPHA:289390 SUPPORT Other
"Extraglandular manifestations include arthritis"
Orphanet definition lists arthritis as an extraglandular manifestation of primary Sjogren disease.
Nervous System 1
Peripheral Neuropathy OCCASIONAL Peripheral neuropathy (HP:0009830)
Both sensory and sensorimotor neuropathies occur. Small fiber neuropathy may be particularly common and underdiagnosed.
Show evidence (2 references)
ORPHA:289390 SUPPORT Other
"Extraglandular manifestations include arthritis, interstitial lung disease, renal disease, and peripheral neuropathy"
Orphanet lists peripheral neuropathy as an extraglandular manifestation of primary Sjogren disease.
PMID:28735431 SUPPORT Human Clinical
"We identified a prevalence of extra-glandular manifestations between 52.6-92.3% in the male population and 50.0-84.6% in children"
Systematic review documenting high prevalence of extraglandular manifestations including neuropathy across different populations.
Constitutional 1
Fatigue VERY_FREQUENT Fatigue (HP:0012378)
Prominent symptom affecting quality of life, often disabling.
Show evidence (1 reference)
PMID:38982205 SUPPORT
"Other common manifestations include pain and fatigue, various systemic manifestations and non-Hodgkin's lymphoma."
Fatigue is identified as a common manifestation in Sjogren syndrome.
Other 6
Parotid Gland Enlargement FREQUENT Enlargement of parotid gland (HP:0011801)
Recurrent or persistent parotid swelling; more common in males and children.
Show evidence (2 references)
PMID:37068269 SUPPORT Human Clinical
"men with pSS had a higher prevalence of parotid enlargement and interstitial lung disease"
Large cohort study documenting parotid enlargement as a manifestation in pSS, with higher prevalence in males.
PMID:28735431 SUPPORT Human Clinical
"children diagnosed with pSS reported less dryness and had a higher prevalence of parotitis, lymphadenopathy and systemic symptoms"
Systematic review confirming parotitis as a prominent manifestation in pediatric pSS.
Interstitial Lung Disease OCCASIONAL Interstitial pneumonitis (HP:0006515)
Severe extraglandular manifestation conferring significant morbidity and mortality. Predominantly fibrotic nonspecific interstitial pneumonia pattern. Risk factors include anti-Ro52 positivity, advanced age, and male sex.
Show evidence (3 references)
PMID:42058207 SUPPORT Human Clinical
"Interstitial lung disease (ILD) is a severe and frequent extraglandular manifestation of primary Sjögren's disease (pSjD), conferring significant morbidity and mortality."
Narrative review establishing ILD as a severe and frequent extraglandular manifestation of pSjD.
PMID:37068269 SUPPORT Human Clinical
"men with pSS had a higher prevalence of parotid enlargement and interstitial lung disease"
Cohort study confirming interstitial lung disease as an extraglandular manifestation, with higher prevalence in males.
ORPHA:289390 SUPPORT Other
"Extraglandular manifestations include arthritis, interstitial lung disease"
Orphanet lists interstitial lung disease as an extraglandular manifestation.
Renal Tubular Acidosis OCCASIONAL Renal tubular acidosis (HP:0001947)
Distal (Type I) renal tubular acidosis is the most common renal manifestation. May present as acute hypokalemic paralysis.
Show evidence (3 references)
PMID:37675753 SUPPORT Human Clinical
"The prevalence of renal involvement in primary Sjogren's syndrome has been reported to range approximately from 10% to 30%."
Reports prevalence of renal involvement in primary Sjogren syndrome at 10-30%.
PMID:37675753 SUPPORT Human Clinical
"Patients with renal involvement in primary Sjogren's syndrome may have renal manifestations, such as renal tubular acidosis (RTA) Type I, TIN, diabetes insipidus, nephrolithiasis, and Fanconi syndrome."
Identifies renal tubular acidosis Type I as a key renal manifestation of pSS.
ORPHA:289390 SUPPORT Other
"Extraglandular manifestations include arthritis, interstitial lung disease, renal disease"
Orphanet lists renal disease as an extraglandular manifestation.
Tubulointerstitial Nephritis OCCASIONAL Tubulointerstitial nephritis (HP:0001970)
Epithelial disease mediated by B and T cells. May also present as immune complex-mediated glomerulopathy.
Show evidence (1 reference)
PMID:37675753 SUPPORT Human Clinical
"It may affect renal function, either as an epithelial disease causing tubulointerstitial nephritis (TIN) or as an immune complex-mediated glomerulopathy."
Describes tubulointerstitial nephritis as a primary mechanism of renal injury in pSS.
Non-Hodgkin Lymphoma Risk OCCASIONAL Non-Hodgkin lymphoma (HP:0012539)
Substantially increased risk of B-cell non-Hodgkin lymphoma, especially MALT lymphoma. Represents the most serious long-term complication.
Show evidence (3 references)
PMID:38542233 SUPPORT
"Primary Sjögren's disease is primarily driven by B-cell activation and is associated with a high risk of developing non-Hodgkin's lymphoma (NHL)."
Directly states the high risk of non-Hodgkin lymphoma in primary Sjogren disease.
PMID:38982205 SUPPORT
"Other common manifestations include pain and fatigue, various systemic manifestations and non-Hodgkin's lymphoma."
Lists non-Hodgkin lymphoma as a manifestation of Sjogren syndrome.
ORPHA:289390 SUPPORT Other
"accompanied by a substantially increased risk to develop B-cell non-Hodgkin lymphoma, especially MALT (mucosa-associated lymphoid tissue) lymphoma"
Orphanet definition confirms substantially increased lymphoma risk.
Palpable Purpura OCCASIONAL Palpable purpura (HP:0031363)
Cutaneous vasculitis with palpable purpura, often associated with cryoglobulinemia and increased lymphoma risk.
Show evidence (1 reference)
PMID:16996579 SUPPORT Human Clinical
"the main diagnostic problems occur in SS patients presenting with arthritis, Raynaud phenomenon, cutaneous features (subacute cutaneous lupus erythematosus, purpura, livedo reticularis, erythema nodosum), interstitial pulmonary disease, and cytopenias (leukopenia, thrombocytopenia)."
Review identifies purpura as a recognized cutaneous manifestation in primary Sjögren's syndrome.
🧬

Genetic Associations

4
HLA-DR3 (Risk Factor)
HLA-DQ2 (Risk Factor)
IRF5 (Risk Factor)
STAT4 (Risk Factor)
💊

Treatments

5
Artificial Tears
Action: supportive care MAXO:0000950
Lubricating eye drops for symptomatic relief of dry eyes.
Pilocarpine
Action: pharmacotherapy MAXO:0000058
Agent: pilocarpine ↗
Muscarinic agonist to stimulate salivary secretion.
Hydroxychloroquine
Action: pharmacotherapy MAXO:0000058
Agent: hydroxychloroquine ↗
For systemic manifestations including arthralgia and fatigue.
Rituximab
Action: pharmacotherapy MAXO:0000058
Agent: rituximab ↗
Anti-CD20 monoclonal antibody for severe systemic disease.
Show evidence (1 reference)
PMID:42058207 PARTIAL Human Clinical
"Emerging therapies, including rituximab and nintedanib, show promise but require further validation in pSjD-ILD cohorts."
Narrative review identifying rituximab as an emerging therapy showing promise in primary Sjögren's disease with interstitial lung disease.
Tofacitinib
Action: pharmacotherapy MAXO:0000058
Agent: tofacitinib ↗
JAK inhibitor targeting the JAK-STAT pathway; phase Ib/IIa trial initiated for Sjögren's disease based on evidence of JAK-STAT pathway activation in salivary gland tissues.
Show evidence (1 reference)
PMID:38527764 SUPPORT Human Clinical
"Predicated on these data, a phase Ib/IIa randomised controlled trial to treat SjD with tofacitinib was initiated."
JAK-STAT pathway study demonstrating that JAK inhibition normalises aberrant interferon signalling in Sjögren's disease tissues, leading to initiation of a clinical trial with tofacitinib.
🔬

Biochemical Markers

5
Anti-Ro/SSA Antibodies (Elevated)
Context: Diagnostic marker; prevalence varies widely across populations (reported 15.7-84.6% in systematic reviews)
Show evidence (1 reference)
PMID:28735431 SUPPORT Human Clinical
"anti-Ro antibodies reported between 15.7-75.0% and 36.4-84.6%"
Systematic review providing anti-Ro antibody prevalence ranges across populations.
Anti-La/SSB Antibodies (Elevated)
Context: More specific for SS, present in 30-40%
Show evidence (1 reference)
PMID:28735431 SUPPORT Human Clinical
"anti-La antibodies between 5.6-51.7% and 27.3-65.4%, in the male and paediatric populations, respectively."
Systematic review providing anti-La antibody prevalence ranges across populations.
Rheumatoid Factor (Elevated)
Context: Present in many patients
Show evidence (1 reference)
PMID:37068269 SUPPORT Human Clinical
"higher titers of antinuclear antibody, anti-Sjögren syndrome A, anti-Ro52, and rheumatoid factor positivity"
Large cohort confirming rheumatoid factor positivity in pSS patients.
Hypergammaglobulinemia (Present)
Context: Polyclonal B cell activation
BAFF (B-cell Activating Factor) (Elevated)
Context: Promotes B-cell survival and autoantibody production
Show evidence (1 reference)
PMID:38542233 PARTIAL
"miR-155 expression correlated with the focus score (FS), as well as BAFF-R and IL-6R expression, which were increased in primary Sjögren's disease patients and in turn related to neoplastic evolution."
Demonstrates elevated BAFF receptor expression in salivary glands of primary Sjögren's disease patients, indicating increased BAFF signaling that drives B-cell activation.
{ }

Source YAML

click to show 
name: Sjogren's Syndrome
creation_date: '2025-12-19T01:12:52Z'
updated_date: '2026-04-30T12:00:00Z'
category: Autoimmune
parents:
- Autoimmune Disease
disease_term:
  preferred_term: Sjogren syndrome
  term:
    id: MONDO:0010030
    label: Sjogren syndrome
description: >-
  A rare systemic autoimmune disease characterized by exocrine gland dysfunction,
  resulting predominately in keratoconjunctivitis sicca and xerostomia, but also
  affecting exocrine glands of the skin, as well as respiratory, urogenital, and
  digestive tract. Extraglandular manifestations include arthritis, interstitial
  lung disease, renal disease, and peripheral neuropathy. The disease is
  accompanied by a substantially increased risk to develop B-cell non-Hodgkin
  lymphoma, especially MALT lymphoma.
prevalence:
- population: General population
  notes: >-
    Rare disease with strong female predominance. Female-to-male ratio approximately 6:1.
  evidence:
  - reference: ORPHA:289390
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A rare systemic autoimmune disease characterized by exocrine gland dysfunction"
    explanation: Orphanet classifies primary Sjogren disease as a rare systemic autoimmune disease.
  - reference: PMID:28735431
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Primary Sjögren's syndrome (pSS) is a chronic multisystem autoimmune rheumatic
      disease characterised by female predominance.
    explanation: Systematic review confirming strong female predominance in primary Sjogren syndrome.
  - reference: PMID:37068269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study included 140 (14.6%) men and 821 (85.4%) women with pSS."
    explanation: Large cohort study of 961 patients confirming approximately 6:1 female-to-male ratio.
pathophysiology:
- name: Exocrine Gland Lymphocytic Infiltration
  description: >-
    CD4+ T cells and B cells infiltrate salivary and lacrimal glands, forming
    ectopic germinal center-like structures. This lymphocytic infiltration
    leads to progressive glandular destruction and dysfunction.
  cell_types:
  - preferred_term: CD4+ T Cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  - preferred_term: B Cell
    term:
      id: CL:0000236
      label: B cell
  biological_processes:
  - preferred_term: Adaptive Immune Response
    term:
      id: GO:0002250
      label: adaptive immune response
  evidence:
  - reference: PMID:33911236
    reference_title: "Epithelial-immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis."
    supports: SUPPORT
    snippet: >-
      The ductal cells of the salivary gland in pSS are characteristically
      surrounded by a CD4+ T cell-rich and B cell-rich infiltrate, implying a degree
      of communication between epithelial cells and immune cells.
    explanation: >-
      Demonstrates the characteristic lymphocytic infiltration
      pattern in salivary glands with both CD4+ T cells and B cells surrounding
      ductal epithelium.
  - reference: ORPHA:289390
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A rare systemic autoimmune disease characterized by exocrine gland dysfunction"
    explanation: Orphanet definition confirms exocrine gland dysfunction as the hallmark of primary Sjogren disease.
- name: Autoantibody Production
  description: >-
    Characteristic autoantibodies include anti-Ro/SSA and anti-La/SSB, which
    target ribonucleoprotein complexes. These antibodies serve as diagnostic
    markers and may contribute to tissue damage through immune complex formation.
  biological_processes:
  - preferred_term: Immunoglobulin Production
    term:
      id: GO:0002377
      label: immunoglobulin production
  evidence:
  - reference: PMID:38542233
    reference_title: "B-Cell Activation Biomarkers in Salivary Glands Are Related to Lymphomagenesis in Primary Sjögren's Disease: A Pilot Monocentric Exploratory Study."
    supports: PARTIAL
    snippet: >-
      Primary Sjögren's disease is primarily driven by B-cell activation and
      is associated with a high risk of developing non-Hodgkin's lymphoma (NHL).
    explanation: >-
      Highlights the central role of B-cell activation in primary
      Sjögren's disease, which drives autoantibody production including
      anti-Ro/SSA and anti-La/SSB antibodies.
  - reference: PMID:28735431
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was a significant variation of positive
      serological markers, with anti-Ro antibodies reported between 15.7-75.0% and
      36.4-84.6%, and anti-La antibodies between 5.6-51.7% and 27.3-65.4%, in the male
      and paediatric populations, respectively.
    explanation: >-
      Systematic review providing prevalence ranges for anti-Ro and anti-La antibody
      positivity across different populations.
- name: Type I Interferon Signature
  description: >-
    Elevated type I interferon activity drives disease pathogenesis through
    activation of plasmacytoid dendritic cells and upregulation of
    interferon-stimulated genes in affected tissues.
  biological_processes:
  - preferred_term: Type I Interferon Response
    term:
      id: GO:0034340
      label: response to type I interferon
  evidence:
  - reference: PMID:33911236
    reference_title: "Epithelial-immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis."
    supports: PARTIAL
    snippet: >-
      Multiple innate immune pathways are likely dysregulated in the salivary
      gland epithelium in pSS, including the nuclear factor-κB pathway, the inflammasome
      and interferon signalling.
    explanation: >-
      Confirms that interferon signaling is a key dysregulated
      pathway in the salivary gland epithelium, contributing to the type I
      interferon signature observed in Sjogren syndrome.
  - reference: PMID:38982205
    reference_title: "Update on the pathophysiology and treatment of primary Sjögren syndrome."
    supports: PARTIAL
    snippet: >-
      Several randomized controlled trials have just been completed or are
      poised to commence evaluating the effectiveness of novel drugs targeting both
      innate and adaptive immune pathways, including pro-inflammatory cytokines, the
      type I interferon system, B cell activation, B cell and T cell co-stimulation
      pathway, and ectopic germinal centre formation.
    explanation: >-
      Highlights type I interferon system as a major therapeutic
      target in Sjogren syndrome, underscoring its central pathogenic role.
- name: Epithelial Cell Dysfunction
  description: >-
    Salivary and lacrimal gland epithelial cells exhibit intrinsic abnormalities
    including aberrant apoptosis, antigen presentation via MHC class II, and
    production of pro-inflammatory cytokines including BAFF.
  cell_types:
  - preferred_term: Epithelial Cell
    term:
      id: CL:0000066
      label: epithelial cell
  biological_processes:
  - preferred_term: Apoptotic Process
    term:
      id: GO:0006915
      label: apoptotic process
  evidence:
  - reference: PMID:33911236
    reference_title: "Epithelial-immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis."
    supports: PARTIAL
    snippet: >-
      B cell infiltrates within the ducts can initiate the development of
      lymphoepithelial lesions, including basal ductal cell hyperplasia. Vice versa,
      the epithelium provides chronic activation signals to the glandular B cell fraction.
    explanation: >-
      Demonstrates that epithelial cells actively participate in
      disease pathogenesis by providing chronic activation signals to immune
      cells, not merely serving as passive targets.
  - reference: PMID:38982205
    reference_title: "Update on the pathophysiology and treatment of primary Sjögren syndrome."
    supports: PARTIAL
    snippet: >-
      Sjögren syndrome or Sjögren disease is a chronic form of autoimmune
      epithelitis characterized by lymphocytic infiltration of the exocrine glands,
      particularly the salivary and lacrimal glands, leading to progressive glandular
      dysfunction and subsequent xerostomia and xerophthalmia.
    explanation: >-
      Defines the disease as an autoimmune epithelitis, emphasizing
      the central role of epithelial cell dysfunction in disease pathology and
      clinical manifestations.
- name: Salivary Gland JAK-STAT Activation and ISG Upregulation
  description: >-
    Salivary gland epithelial cells and immune cells in Sjögren's disease exhibit
    cell type-specific upregulation of interferon-stimulated genes (ISGs) and
    aberrant activation of the JAK-STAT signaling pathway, correlating with
    clinical severity indicators including focus score and anti-SSA seropositivity.
    JAK inhibition normalises this signalling, establishing the IFN-JAK-STAT axis
    as a primary pathogenic driver and therapeutic target.
  cell_types:
  - preferred_term: Salivary Gland Epithelial Cell
    term:
      id: CL:0000066
      label: epithelial cell
  biological_processes:
  - preferred_term: JAK-STAT Signaling Cascade
    term:
      id: GO:0007259
      label: cell surface receptor signaling pathway via JAK-STAT
  evidence:
  - reference: PMID:38527764
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SjD patients' tissues exhibit increased expression of ISGs and
      activation of the JAK-STAT pathway in a cell type-dependent manner. JAKi
      normalises this aberrant signalling at the tissue level and in PBMCs, suggesting
      a putative viable therapy for SjD, targeting both glandular and extraglandular
      symptoms.
    explanation: >-
      Human tissue study demonstrating cell type-specific JAK-STAT pathway activation
      and ISG upregulation in Sjögren's disease salivary glands, with JAK inhibition
      normalising aberrant signalling and prompting a tofacitinib clinical trial.
- name: B-cell Lymphomagenesis
  description: >-
    Chronic B-cell activation and ectopic germinal center formation in salivary
    glands create a microenvironment that promotes clonal B-cell expansion and
    progression to mucosa-associated lymphoid tissue (MALT) lymphoma. This
    represents the most serious complication of the disease.
  cell_types:
  - preferred_term: B Cell
    term:
      id: CL:0000236
      label: B cell
  biological_processes:
  - preferred_term: B Cell Proliferation
    term:
      id: GO:0042100
      label: B cell proliferation
  downstream:
  - target: Non-Hodgkin Lymphoma Risk
  evidence:
  - reference: PMID:38542233
    reference_title: "B-Cell Activation Biomarkers in Salivary Glands Are Related to Lymphomagenesis in Primary Sjögren's Disease: A Pilot Monocentric Exploratory Study."
    supports: SUPPORT
    snippet: >-
      miR-155 expression correlated with the focus score (FS), as well as
      BAFF-R and IL-6R expression, which were increased in primary Sjögren's disease
      patients and in turn related to neoplastic evolution.
    explanation: >-
      Demonstrates that B-cell activation biomarkers in salivary glands correlate with
      lymphomagenesis risk in primary Sjogren disease.
  - reference: PMID:33911236
    reference_title: "Epithelial-immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis."
    supports: SUPPORT
    snippet: >-
      This continuous stimulation might ultimately
      drive the development of mucosa-associated lymphoid tissue lymphoma.
    explanation: Describes how chronic epithelial-immune stimulation drives MALT lymphoma development.
  - reference: ORPHA:289390
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "accompanied by a substantially increased risk to develop B-cell non-Hodgkin lymphoma, especially MALT (mucosa-associated lymphoid tissue) lymphoma"
    explanation: Orphanet definition confirms the substantially increased lymphoma risk in primary Sjogren disease.
phenotypes:
- name: Xerostomia
  category: Oral
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Xerostomia
    term:
      id: HP:0000217
      label: Xerostomia
  notes: Dry mouth due to salivary gland dysfunction; a cardinal feature of the disease.
  evidence:
  - reference: PMID:38982205
    reference_title: "Update on the pathophysiology and treatment of primary Sjögren syndrome."
    supports: SUPPORT
    snippet: >-
      Sjögren syndrome or Sjögren disease is a chronic form of autoimmune
      epithelitis characterized by lymphocytic infiltration of the exocrine glands,
      particularly the salivary and lacrimal glands, leading to progressive glandular
      dysfunction and subsequent xerostomia and xerophthalmia.
    explanation: >-
      Xerostomia is listed as a primary clinical manifestation
      resulting from progressive salivary gland dysfunction.
  - reference: ORPHA:289390
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "resulting predominately in keratoconjunctivitis sicca and xerostomia"
    explanation: Orphanet definition lists xerostomia as a predominant manifestation.
  - reference: PMID:37068269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Women with pSS demonstrated a higher prevalence of dry mouth, dry eyes,
      arthralgia, and dental caries
    explanation: Large cohort study confirming high prevalence of dry mouth in pSS patients.
- name: Keratoconjunctivitis Sicca
  category: Ophthalmological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Keratoconjunctivitis Sicca
    term:
      id: HP:0001097
      label: Keratoconjunctivitis sicca
  notes: Dry eyes are a cardinal feature of the disease, present in the majority of patients.
  evidence:
  - reference: ORPHA:289390
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "resulting predominately in keratoconjunctivitis sicca and xerostomia"
    explanation: Orphanet definition lists keratoconjunctivitis sicca as a predominant manifestation.
  - reference: PMID:37068269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Women with pSS demonstrated a higher prevalence of dry mouth, dry eyes,
      arthralgia, and dental caries
    explanation: Large cohort study confirming high prevalence of dry eyes in pSS.
- name: Fatigue
  category: Systemic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  notes: Prominent symptom affecting quality of life, often disabling.
  evidence:
  - reference: PMID:38982205
    reference_title: "Update on the pathophysiology and treatment of primary Sjögren syndrome."
    supports: SUPPORT
    snippet: >-
      Other common manifestations include pain and fatigue, various systemic
      manifestations and non-Hodgkin's lymphoma.
    explanation: Fatigue is identified as a common manifestation in Sjogren syndrome.
- name: Arthritis
  category: Musculoskeletal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Arthritis
    term:
      id: HP:0001369
      label: Arthritis
  notes: Non-erosive polyarthritis, predominantly affecting small joints.
  evidence:
  - reference: ORPHA:289390
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Extraglandular manifestations include arthritis"
    explanation: Orphanet definition lists arthritis as an extraglandular manifestation of primary Sjogren disease.
- name: Parotid Gland Enlargement
  category: Oral
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Enlargement of parotid gland
    term:
      id: HP:0011801
      label: Enlargement of parotid gland
  notes: Recurrent or persistent parotid swelling; more common in males and children.
  evidence:
  - reference: PMID:37068269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      men with pSS had a
      higher prevalence of parotid enlargement and interstitial lung disease
    explanation: >-
      Large cohort study documenting parotid enlargement as a manifestation in pSS,
      with higher prevalence in males.
  - reference: PMID:28735431
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      children diagnosed with pSS
      reported less dryness and had a higher prevalence of parotitis, lymphadenopathy
      and systemic symptoms
    explanation: Systematic review confirming parotitis as a prominent manifestation in pediatric pSS.
- name: Dental Caries
  category: Oral
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Dental caries
    term:
      id: HP:0000670
      label: Carious teeth
  notes: Accelerated dental decay secondary to reduced salivary flow.
  evidence:
  - reference: PMID:37068269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Women with pSS demonstrated a higher prevalence of dry mouth, dry eyes,
      arthralgia, and dental caries
    explanation: Large cohort study documenting dental caries as a significant complication in pSS.
- name: Interstitial Lung Disease
  category: Respiratory
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Interstitial pneumonitis
    term:
      id: HP:0006515
      label: Interstitial pneumonitis
  notes: >-
    Severe extraglandular manifestation conferring significant morbidity and
    mortality. Predominantly fibrotic nonspecific interstitial pneumonia pattern.
    Risk factors include anti-Ro52 positivity, advanced age, and male sex.
  evidence:
  - reference: PMID:42058207
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Interstitial lung disease (ILD) is a severe and frequent extraglandular
      manifestation of primary Sjögren's disease (pSjD), conferring significant
      morbidity and mortality.
    explanation: Narrative review establishing ILD as a severe and frequent extraglandular manifestation of pSjD.
  - reference: PMID:37068269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      men with pSS had a
      higher prevalence of parotid enlargement and interstitial lung disease
    explanation: >-
      Cohort study confirming interstitial lung disease as an extraglandular manifestation,
      with higher prevalence in males.
  - reference: ORPHA:289390
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Extraglandular manifestations include arthritis, interstitial lung disease"
    explanation: Orphanet lists interstitial lung disease as an extraglandular manifestation.
- name: Peripheral Neuropathy
  category: Neurological
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  notes: Both sensory and sensorimotor neuropathies occur. Small fiber neuropathy may be particularly common and underdiagnosed.
  evidence:
  - reference: ORPHA:289390
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Extraglandular manifestations include arthritis, interstitial lung disease, renal disease, and peripheral neuropathy"
    explanation: Orphanet lists peripheral neuropathy as an extraglandular manifestation of primary Sjogren disease.
  - reference: PMID:28735431
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a prevalence of extra-glandular manifestations
      between 52.6-92.3% in the male population and 50.0-84.6% in children
    explanation: >-
      Systematic review documenting high prevalence of extraglandular manifestations
      including neuropathy across different populations.
- name: Renal Tubular Acidosis
  category: Renal
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Renal tubular acidosis
    term:
      id: HP:0001947
      label: Renal tubular acidosis
  notes: Distal (Type I) renal tubular acidosis is the most common renal manifestation. May present as acute hypokalemic paralysis.
  evidence:
  - reference: PMID:37675753
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The prevalence of renal involvement in primary Sjogren's syndrome has
      been reported to range approximately from 10% to 30%.
    explanation: Reports prevalence of renal involvement in primary Sjogren syndrome at 10-30%.
  - reference: PMID:37675753
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with renal
      involvement in primary Sjogren's syndrome may have renal manifestations, such as
      renal tubular acidosis (RTA) Type I, TIN, diabetes insipidus, nephrolithiasis,
      and Fanconi syndrome.
    explanation: Identifies renal tubular acidosis Type I as a key renal manifestation of pSS.
  - reference: ORPHA:289390
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Extraglandular manifestations include arthritis, interstitial lung disease, renal disease"
    explanation: Orphanet lists renal disease as an extraglandular manifestation.
- name: Tubulointerstitial Nephritis
  category: Renal
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Tubulointerstitial nephritis
    term:
      id: HP:0001970
      label: Tubulointerstitial nephritis
  notes: Epithelial disease mediated by B and T cells. May also present as immune complex-mediated glomerulopathy.
  evidence:
  - reference: PMID:37675753
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It may affect renal function, either as an
      epithelial disease causing tubulointerstitial nephritis (TIN) or as an immune
      complex-mediated glomerulopathy.
    explanation: Describes tubulointerstitial nephritis as a primary mechanism of renal injury in pSS.
- name: Non-Hodgkin Lymphoma Risk
  category: Hematological
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Non-Hodgkin lymphoma
    term:
      id: HP:0012539
      label: Non-Hodgkin lymphoma
  notes: Substantially increased risk of B-cell non-Hodgkin lymphoma, especially MALT lymphoma. Represents the most serious long-term complication.
  evidence:
  - reference: PMID:38542233
    reference_title: "B-Cell Activation Biomarkers in Salivary Glands Are Related to Lymphomagenesis in Primary Sjögren's Disease."
    supports: SUPPORT
    snippet: >-
      Primary Sjögren's disease is primarily driven by B-cell activation and
      is associated with a high risk of developing non-Hodgkin's lymphoma (NHL).
    explanation: Directly states the high risk of non-Hodgkin lymphoma in primary Sjogren disease.
  - reference: PMID:38982205
    supports: SUPPORT
    snippet: >-
      Other common manifestations include pain and fatigue, various systemic
      manifestations and non-Hodgkin's lymphoma.
    explanation: Lists non-Hodgkin lymphoma as a manifestation of Sjogren syndrome.
  - reference: ORPHA:289390
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "accompanied by a substantially increased risk to develop B-cell non-Hodgkin lymphoma, especially MALT (mucosa-associated lymphoid tissue) lymphoma"
    explanation: Orphanet definition confirms substantially increased lymphoma risk.
- name: Lymphadenopathy
  category: Hematological
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
  notes: May be generalized or regional; requires evaluation to exclude lymphoma.
  evidence:
  - reference: PMID:28735431
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      children diagnosed with pSS
      reported less dryness and had a higher prevalence of parotitis, lymphadenopathy
      and systemic symptoms
    explanation: >-
      Systematic review documenting lymphadenopathy as a manifestation of pSS,
      particularly prominent in pediatric populations.
- name: Raynaud Phenomenon
  category: Vascular
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Raynaud phenomenon
    term:
      id: HP:0030880
      label: Raynaud phenomenon
  notes: Vasospastic episodes of the digits; associated with more severe systemic disease.
  evidence:
  - reference: PMID:16996579
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the main diagnostic problems occur in SS patients
      presenting with arthritis, Raynaud phenomenon, cutaneous features (subacute
      cutaneous lupus erythematosus, purpura, livedo reticularis, erythema nodosum),
      interstitial pulmonary disease, and cytopenias (leukopenia, thrombocytopenia).
    explanation: Review of extraglandular manifestations identifies Raynaud phenomenon as a major clinical feature in primary Sjögren's syndrome.
- name: Palpable Purpura
  category: Dermatological
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Palpable purpura
    term:
      id: HP:0031363
      label: Palpable purpura
  notes: Cutaneous vasculitis with palpable purpura, often associated with cryoglobulinemia and increased lymphoma risk.
  evidence:
  - reference: PMID:16996579
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the main diagnostic problems occur in SS patients
      presenting with arthritis, Raynaud phenomenon, cutaneous features (subacute
      cutaneous lupus erythematosus, purpura, livedo reticularis, erythema nodosum),
      interstitial pulmonary disease, and cytopenias (leukopenia, thrombocytopenia).
    explanation: Review identifies purpura as a recognized cutaneous manifestation in primary Sjögren's syndrome.
biochemical:
- name: Anti-Ro/SSA Antibodies
  presence: Elevated
  context: Diagnostic marker; prevalence varies widely across populations (reported 15.7-84.6% in systematic reviews)
  evidence:
  - reference: PMID:28735431
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      anti-Ro antibodies reported between 15.7-75.0% and
      36.4-84.6%
    explanation: Systematic review providing anti-Ro antibody prevalence ranges across populations.
- name: Anti-La/SSB Antibodies
  presence: Elevated
  context: More specific for SS, present in 30-40%
  evidence:
  - reference: PMID:28735431
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      anti-La antibodies between 5.6-51.7% and 27.3-65.4%, in the male
      and paediatric populations, respectively.
    explanation: Systematic review providing anti-La antibody prevalence ranges across populations.
- name: Rheumatoid Factor
  presence: Elevated
  context: Present in many patients
  evidence:
  - reference: PMID:37068269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      higher titers of antinuclear antibody, anti-Sjögren syndrome A, anti-Ro52, and
      rheumatoid factor positivity
    explanation: Large cohort confirming rheumatoid factor positivity in pSS patients.
- name: Hypergammaglobulinemia
  presence: Present
  context: Polyclonal B cell activation
- name: BAFF (B-cell Activating Factor)
  presence: Elevated
  context: Promotes B-cell survival and autoantibody production
  evidence:
  - reference: PMID:38542233
    reference_title: "B-Cell Activation Biomarkers in Salivary Glands Are Related to Lymphomagenesis in Primary Sjögren's Disease: A Pilot Monocentric Exploratory Study."
    supports: PARTIAL
    snippet: >-
      miR-155 expression correlated with the focus score (FS), as well as
      BAFF-R and IL-6R expression, which were increased in primary Sjögren's disease
      patients and in turn related to neoplastic evolution.
    explanation: >-
      Demonstrates elevated BAFF receptor expression in salivary
      glands of primary Sjögren's disease patients, indicating increased BAFF
      signaling that drives B-cell activation.
genetic:
- name: HLA-DR3
  association: Risk Factor
- name: HLA-DQ2
  association: Risk Factor
- name: IRF5
  association: Risk Factor
- name: STAT4
  association: Risk Factor
treatments:
- name: Artificial Tears
  description: Lubricating eye drops for symptomatic relief of dry eyes.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
- name: Pilocarpine
  description: Muscarinic agonist to stimulate salivary secretion.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: pilocarpine
      term:
        id: CHEBI:8207
        label: (+)-pilocarpine
- name: Hydroxychloroquine
  description: For systemic manifestations including arthralgia and fatigue.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: hydroxychloroquine
      term:
        id: CHEBI:5801
        label: hydroxychloroquine
- name: Rituximab
  description: Anti-CD20 monoclonal antibody for severe systemic disease.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: rituximab
      term:
        id: NCIT:C1702
        label: Rituximab
  evidence:
  - reference: PMID:42058207
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Emerging therapies, including rituximab and nintedanib, show promise but
      require further validation in pSjD-ILD cohorts.
    explanation: >-
      Narrative review identifying rituximab as an emerging therapy showing promise
      in primary Sjögren's disease with interstitial lung disease.
- name: Tofacitinib
  description: JAK inhibitor targeting the JAK-STAT pathway; phase Ib/IIa trial initiated for Sjögren's disease based on evidence of JAK-STAT pathway activation in salivary gland tissues.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: tofacitinib
      term:
        id: CHEBI:71200
        label: tofacitinib
  evidence:
  - reference: PMID:38527764
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Predicated on these data, a phase Ib/IIa randomised controlled trial
      to treat SjD with tofacitinib was initiated.
    explanation: >-
      JAK-STAT pathway study demonstrating that JAK inhibition normalises aberrant
      interferon signalling in Sjögren's disease tissues, leading to initiation of
      a clinical trial with tofacitinib.
classifications:
  harrisons_chapter:
  - classification_value: musculoskeletal system disorder
  - classification_value: connective tissue disease
  - classification_value: autoimmune disease
references:
- reference: DOI:10.1016/j.heliyon.2024.e36220
  title: "A comprehensive review of Sjögren's syndrome: Classification criteria, risk factors, and signaling pathways"
  findings: []
- reference: DOI:10.1136/ard-2023-224842
  title: Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren's disease
  findings: []
- reference: DOI:10.1186/s13075-024-03283-z
  title: B cell receptor repertoire analysis in primary Sjogren's syndrome salivary glands identifies repertoire features associated with clinical activity
  findings: []
- reference: DOI:10.21203/rs.3.rs-4371628/v1
  title: "Interplay of Interferon signalling gene expression, DNA Methylation, and inflammatory cytokines in Sjögren's Syndrome: a multi-omics Mendelian randomization study"
  findings: []
- reference: DOI:10.3389/fimmu.2024.1405126
  title: Advances in cellular and molecular pathways of salivary gland damage in Sjögren's syndrome
  findings: []
- reference: DOI:10.55563/clinexprheumatol/cmmkod
  title: Role of TLR7 in the pathogenesis of primary Sjögren's syndrome
  findings: []
- reference: DOI:10.55563/clinexprheumatol/i8iszc
  title: "Pathogenesis of Sjögren's disease: one year in review 2024"
  findings: []
📚

References & Deep Research

References

7
DOI:10.1016/j.heliyon.2024.e36220
A comprehensive review of Sjögren's syndrome: Classification criteria, risk factors, and signaling pathways
No top-level findings curated for this source.
DOI:10.1136/ard-2023-224842
Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren's disease
No top-level findings curated for this source.
DOI:10.1186/s13075-024-03283-z
B cell receptor repertoire analysis in primary Sjogren's syndrome salivary glands identifies repertoire features associated with clinical activity
No top-level findings curated for this source.
DOI:10.21203/rs.3.rs-4371628/v1
Interplay of Interferon signalling gene expression, DNA Methylation, and inflammatory cytokines in Sjögren's Syndrome: a multi-omics Mendelian randomization study
No top-level findings curated for this source.
DOI:10.3389/fimmu.2024.1405126
Advances in cellular and molecular pathways of salivary gland damage in Sjögren's syndrome
No top-level findings curated for this source.
DOI:10.55563/clinexprheumatol/cmmkod
Role of TLR7 in the pathogenesis of primary Sjögren's syndrome
No top-level findings curated for this source.
DOI:10.55563/clinexprheumatol/i8iszc
Pathogenesis of Sjögren's disease: one year in review 2024
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Sjogren's Syndrome
  • Category: Autoimmune
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 16

Key Pathophysiology Nodes

  • Exocrine Gland Lymphocytic Infiltration
  • Autoantibody Production
  • Type I Interferon Signature
  • Epithelial Cell Dysfunction
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1016/j.heliyon.2024.e36220
  • DOI:10.1136/ard-2023-224842
  • DOI:10.1186/s13075-024-03283-z
  • DOI:10.21203/rs.3.rs-4371628/v1
  • DOI:10.3389/fimmu.2024.1405126
  • DOI:10.55563/clinexprheumatol/cmmkod
  • DOI:10.55563/clinexprheumatol/i8iszc
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 14 citations 2025-12-18T09:52:36.367805

Disease Pathophysiology Research Report

Target Disease - Disease Name: Sjogren's Syndrome (primary Sjögren’s disease, SjD) - MONDO ID: MONDO:0005268 - Category: Autoimmune

Pathophysiology description (narrative) Primary Sjögren’s disease is an autoimmune exocrinopathy driven by epithelial cell–intrinsic innate immune activation and sustained cross-talk with innate and adaptive lymphocytes, culminating in focal lymphocytic sialadenitis, loss of secretory acini, tissue remodeling/fibrosis, systemic features, and an elevated risk of B‑cell lymphoma. Multi-omic and single-cell studies from 2023–2024 converge on a pathogenic axis centered on type I interferon (IFN) signaling and JAK–STAT activation in salivary gland epithelial cells (SGECs) and circulating myeloid cells, with epithelial PRR pathways (TLR7/8/9; cGAS–STING) acting as upstream triggers. This IFN-dominant milieu amplifies BAFF/APRIL-mediated B-cell survival, T follicular helper (Tfh) support, ectopic germinal center/TLS formation, clonal B-cell expansion, and cytotoxic CD8+ tissue-resident memory (Trm) cell–mediated epithelial damage, promoting disease chronicity and complications (Ann Rheum Dis, Aug 2024; Clin Exp Rheumatol, Nov 2024) (zhao2024acomprehensivereview pages 3-4, baldini2024pathogenesisofsjögrens pages 5-7, baldini2024pathogenesisofsjögrens pages 3-4, baldini2024pathogenesisofsjögrens pages 2-3).

Key concepts and definitions with current understanding - Epithelial cell–intrinsic autoimmunity: SGECs are not passive targets; they upregulate MHC II/co-stimulatory molecules, produce type I IFN and chemokines, and misexpress molecules such as LAMP3 under IFN stimulation, establishing positive feedback with endosomal TLR7 and sustaining the IFN signature (Clin Exp Rheumatol, Nov 2024) (baldini2024pathogenesisofsjögrens pages 3-4, baldini2024pathogenesisofsjögrens pages 2-3). - Type I IFN signature and JAK–STAT activation: Elevated ISGs in minor salivary glands and blood, correlating with focus score and anti-SSA seropositivity; ex vivo, JAK inhibition normalizes pSTAT and ISGs in SGECs and PBMCs, supporting a targetable pathway (Ann Rheum Dis, Aug 2024; URL: https://doi.org/10.1136/ard-2023-224842) (zhao2024acomprehensivereview pages 3-4). - PRR pathways: TLR7/8/9 and cGAS–STING link nucleic-acid sensing and mitochondrial/ER stress to type I IFN production in SGECs and pDCs; these axes are implicated in initiating and sustaining glandular inflammation (Clin Exp Rheumatol, Sep 2024; Front Immunol, Jul 2024) (qi2024advancesincellular pages 2-4, zhao2024acomprehensivereview pages 3-4). - Adaptive immune dysregulation: Tfh–B cell synapses drive local affinity maturation in TLS; BAFF/APRIL signaling sustains plasmablast/plasma cell survival; gland-infiltrating BCR repertoires display clonal expansion and repertoire biases associated with clinical activity (Arthritis Res Ther, Mar 2024) (qi2024advancesincellular pages 2-4). - Cytotoxic CD8+ Trm: Spatial and functional studies show expanded CD8+CD103+ Trm expressing GZMB/GZMK and IFN-γ, localized within inflammatory foci and contributing to epithelial injury; anti‑CD103 blockade reduces Trm and improves salivary flow in models (Ann Rheum Dis, Oct 2024) (zhao2024acomprehensivereview pages 3-4). - Genetics/epigenetics: Strong HLA class II associations in anti‑SSA+ SjD, and non‑HLA loci (IRF5, STAT4) implicate IFN and antigen presentation pathways; ISGs show DNA hypomethylation in immune and epithelial cells, correlating with severity (Nat Rev Rheumatol, Mar 2023; Front Immunol, Mar 2024; Heliyon, Sep 2024) (zhao2024acomprehensivereview pages 3-4, baldini2024pathogenesisofsjögrens pages 2-3).

Recent developments (2023–2024) and latest research - One‑year pathogenesis review 2024 synthesizes new single-cell/spatial evidence: SGEC LAMP3/IFN loops, mitochondrial dysfunction, m6A-dependent IFN control, myeloid skewing (NLRP3+ clusters), and cytotoxic GZMK+ CD8+ T-cell–driven acinar loss; links to pre‑lymphomatous lesions and emergence of MALT lymphoma clones (Clin Exp Rheumatol, Nov 2024; https://doi.org/10.55563/clinexprheumatol/i8iszc) (baldini2024pathogenesisofsjögrens pages 5-7, baldini2024pathogenesisofsjögrens pages 3-4, baldini2024pathogenesisofsjögrens pages 2-3). - Interventional immune signaling: Human tissue and ex vivo work demonstrate that JAK inhibition corrects IFN–JAK–STAT activity in glands and PBMCs, prompting a phase Ib/IIa trial of tofacitinib (Ann Rheum Dis, Aug 2024; https://doi.org/10.1136/ard-2023-224842) (zhao2024acomprehensivereview pages 3-4). - BCR repertoire and single-cell atlases: Paired scRNA/BCR-seq identifies gland-specific BCR expansions, altered isotype usage (reduced IgA2), and light-chain skewing correlating with disease activity (Arthritis Res Ther, Mar 2024; https://doi.org/10.1186/s13075-024-03283-z). Single-cell profiles (iScience, Oct 2023; J Transl Autoimmunity, Dec 2024) refine immune–stromal heterogeneity in labial glands (qi2024advancesincellular pages 2-4). - PRR specialization: TLR7-focused review highlights endosomal ssRNA sensing in pDCs and SGECs with MyD88-dependent induction of IFN-I, integrating with the IFN signature observed in SjD (Clin Exp Rheumatol, Sep 2024; https://doi.org/10.55563/clinexprheumatol/cmmkod) (qi2024advancesincellular pages 2-4). - Multi-omics epigenetics: Integrative MR suggests causal interplay between IFN-signaling gene expression, DNA methylation, and inflammatory cytokines in SjD, nominating SH2B3, LGALS9, CD40, GRB2, DTX3L in blood and APOBEC3G, IFI27L2, TMEM50B, SH2B3 in gland tissue as IFN-associated causal genes (May 2024; https://doi.org/10.21203/rs.3.rs-4371628/v1) (he2024interplayofinterferon pages 18-21).

Current applications and real-world implementations - Mechanism-based therapy: JAK inhibitors to modulate glandular IFN–JAK–STAT signaling; B cell–directed approaches (rituximab strategies and BAFF/APRIL-targeted agents) for hyperactive B-cell states and TLS-positive disease, with biomarker guidance by IFN signatures and BCR features (Ann Rheum Dis, 2024; Clin Exp Rheumatol, 2024) (zhao2024acomprehensivereview pages 3-4, baldini2024pathogenesisofsjögrens pages 5-7). - Biomarker-guided stratification: IFN signatures in glands and blood, chemokines (CXCL10, CXCL13), BAFF levels, and BCR repertoire metrics associate with activity, serostatus, and lymphoma risk; DNA methylation of ISGs in salivary glands reflects severity (Front Immunol, 2024; Heliyon, 2024) (qi2024advancesincellular pages 2-4, zhao2024acomprehensivereview pages 3-4).

Expert opinions and analysis from authoritative sources - “The innate immune system plays a crucial role in initiation… amplification requires continual interaction between innate and adaptive immunity” and ectopic GC-like structures are “critically involved in autoreactive B cell activation… associated with progression towards B cell lymphomas” (Clin Exp Rheumatol, Nov 2024) (baldini2024pathogenesisofsjögrens pages 5-7). - Human tissue data show that “activated JAK–STAT pathway in SjD MSGs… elevated ISG expression associated with focus scores and anti-SSA positivity” and “JAKi normalises this aberrant signalling at the tissue level and in PBMCs” (Ann Rheum Dis, Aug 2024) (zhao2024acomprehensivereview pages 3-4).

Relevant statistics and data from recent studies - Gland and blood IFN–JAK–STAT activation correlates with histology and serology; ex vivo JAKi normalized basal pSTAT levels in SjD-derived SGECs and PBMCs and reduced IFN-β exaggerated responses in SGECs without cytotoxicity (Ann Rheum Dis, 2024) (zhao2024acomprehensivereview pages 3-4). - BCR repertoire work demonstrated decreased IgA2 usage in glandular B cells and a positive correlation between κ/λ light chain usage and clinical activity (Arthritis Res Ther, 2024) (qi2024advancesincellular pages 2-4). - Spatial/single-cell analyses identified CD8+CD103+ Trm accumulation with GZMB/GZMK/IFN-γ expression; anti‑CD103 intervention reduced Trm, glandular damage and improved flow in the ESS model (Ann Rheum Dis, 2024) (zhao2024acomprehensivereview pages 3-4).

  1. Core Pathophysiology
  2. Primary mechanisms: epithelial PRR activation (TLR7/8/9; cGAS–STING), IFN–JAK–STAT signaling, BAFF/APRIL-driven B-cell survival, Tfh-mediated help, TLS/ectopic GCs, cytotoxic CD8+ Trm-mediated epithelial injury, and epigenetic ISG hypomethylation (Clin Exp Rheumatol, 2024; Front Immunol, 2024; Ann Rheum Dis, 2024) (qi2024advancesincellular pages 2-4, baldini2024pathogenesisofsjögrens pages 5-7, baldini2024pathogenesisofsjögrens pages 3-4, baldini2024pathogenesisofsjögrens pages 2-3, zhao2024acomprehensivereview pages 3-4).
  3. Dysregulated pathways: IFN-α/β signaling; TLR7/8/9–MyD88; cGAS–STING–TBK1–IRF3; BAFF/APRIL–BAFF-R/TACI/BCMA; Tfh–IL-21–BCR; JAK–STAT; inflammasome/NLRP3; EMT/TGF‑β–SMAD; chemokine axes (CXCL10/CXCL13) (Front Immunol, 2024; Heliyon, 2024) (qi2024advancesincellular pages 2-4, zhao2024acomprehensivereview pages 3-4).

  4. Affected cellular processes: antigen presentation by SGECs, ISG transcriptional programs, BCR diversification and clonal expansion, cytotoxic granule pathways in Trm, ER/mitochondrial stress, EMT and fibrosis (Clin Exp Rheumatol, 2024; Front Immunol, 2024) (baldini2024pathogenesisofsjögrens pages 5-7, qi2024advancesincellular pages 2-4).

  5. Key Molecular Players

  6. Genes/Proteins (HGNC): IRF5; STAT4; HLA-DQA1/DQB1; TNFSF13B (BAFF); TNFSF13 (APRIL); TNFRSF13C (BAFF-R); TNFRSF13B (TACI); TNFRSF17 (BCMA); CXCL10; CXCL13; IL21; LAMP3 (Clin Exp Rheumatol, 2024; Heliyon, 2024) (baldini2024pathogenesisofsjögrens pages 5-7, zhao2024acomprehensivereview pages 3-4).
  7. Chemical Entities (CHEBI/drug class): JAK inhibitors (class); BAFF/APRIL inhibitors (class) (Ann Rheum Dis, 2024) (zhao2024acomprehensivereview pages 3-4).
  8. Cell Types (CL): salivary gland epithelial cells; plasmacytoid dendritic cells; monocytes/macrophages; Tfh cells; CD8+ Trm cells; B cells/plasmablasts/plasma cells (Clin Exp Rheumatol, 2024; Front Immunol, 2024) (baldini2024pathogenesisofsjögrens pages 5-7, qi2024advancesincellular pages 2-4).

  9. Anatomical Locations (UBERON): labial and parotid salivary glands; lacrimal gland (Heliyon, 2024) (zhao2024acomprehensivereview pages 3-4).

  10. Biological Processes (GO terms)

  11. GO: type I interferon signaling pathway; GO: toll-like receptor signaling pathway (TLR7/8/9); GO: cGAS–STING DNA sensing; GO: B cell activation; GO: germinal center formation; GO: T cell activation; GO: JAK–STAT cascade; GO: epithelial to mesenchymal transition; GO: inflammatory response; GO: antigen processing and presentation via MHC class II (Front Immunol, 2024; Clin Exp Rheumatol, 2024) (qi2024advancesincellular pages 2-4, baldini2024pathogenesisofsjögrens pages 5-7).

  12. Cellular Components

  13. Key cellular locales: endosomes (TLR7/8/9), ER and mitochondria (stress, ER–mitochondrial crosstalk), cytosol (cGAS–STING), plasma membrane (BAFF-R/TACI/BCMA), extracellular space (cytokines/chemokines), epithelial tight junctions and basal membrane interfaces (Heliyon, 2024; Clin Exp Rheumatol, 2024) (zhao2024acomprehensivereview pages 3-4, baldini2024pathogenesisofsjögrens pages 3-4).

  14. Disease Progression

  15. Sequence of events: epithelial PRR/IFN activation → chemokine release (CXCL10/CXCL13), pDC/myeloid recruitment → IFN–JAK–STAT amplification → B-cell hyperactivity (BAFF/APRIL), Tfh help → TLS/ectopic GC formation, BCR clonal expansion and plasma cell survival → cytotoxic CD8+ Trm–mediated acinar injury → chronic sialadenitis with fibrosis/EMT → systemic features; in a subset, pre-lymphomatous lymphoepithelial lesions and MALT lymphoma (Clin Exp Rheumatol, 2024; Front Immunol, 2024) (baldini2024pathogenesisofsjögrens pages 5-7, qi2024advancesincellular pages 2-4).

  16. Stages/phases: early epithelial/IFN phase; adaptive/TLS expansion phase; remodeling/fibrotic phase; lymphoma risk phase in TLS-high, RF+ clones (Clin Exp Rheumatol, 2024) (baldini2024pathogenesisofsjögrens pages 5-7, baldini2024pathogenesisofsjögrens pages 3-4).

  17. Phenotypic Manifestations

  18. Clinical phenotypes (HP): keratoconjunctivitis sicca; xerostomia; salivary gland enlargement; fatigue; arthralgia; extraglandular involvement (interstitial lung disease, neuropathy, renal tubular acidosis); increased risk of B‑cell lymphoma (Heliyon, 2024; Clin Exp Rheumatol, 2024) (zhao2024acomprehensivereview pages 3-4, baldini2024pathogenesisofsjögrens pages 5-7).
  19. Mechanistic links: sicca arises from acinar/ductal injury by CD8+ Trm cytotoxicity and IFN/chemokine-driven inflammation; hypergammaglobulinemia and autoantibodies (anti‑SSA/SSB) reflect Tfh–BAFF/APRIL–B cell activation; systemic features correlate with systemic IFN signatures; lymphoma risk associates with TLS, parotid lymphoepithelial lesions, RF+ clonotypes and BCR hypermutation (Clin Exp Rheumatol, 2024; Arthritis Res Ther, 2024) (baldini2024pathogenesisofsjögrens pages 5-7, qi2024advancesincellular pages 2-4).

Gene/protein annotations with ontology terms (HGNC) and evidence - IRF5 (HGNC:6117): innate IFN pathway regulator; risk locus in SjD (Nat Rev Rheumatol, Mar 2023) (baldini2024pathogenesisofsjögrens pages 2-3). - STAT4 (HGNC:11364): downstream of cytokine receptors; SjD risk locus; ties to Th1/Tfh programs (Nat Rev Rheumatol, 2023) (baldini2024pathogenesisofsjögrens pages 2-3). - HLA-DQA1/HLA-DQB1 (HGNC): antigen presentation; strongest in anti‑SSA+ patients (Heliyon, Sep 2024) (zhao2024acomprehensivereview pages 3-4). - TNFSF13B (BAFF), TNFSF13 (APRIL), TNFRSF13C (BAFF-R), TNFRSF13B (TACI), TNFRSF17 (BCMA): B‑cell survival axis in glands (Front Immunol, Jul 2024) (qi2024advancesincellular pages 2-4). - LAMP3: IFN-inducible epithelial molecule; misexpression amplifies TLR7/IFN loops (Clin Exp Rheumatol, Nov 2024) (baldini2024pathogenesisofsjögrens pages 3-4). - CXCL10/CXCL13/IL21: chemokines/cytokines recruiting/educating T and B cells in TLS (Heliyon, Sep 2024) (zhao2024acomprehensivereview pages 3-4).

Phenotype associations (HP terms) and evidence - HP:0001098 Keratoconjunctivitis sicca; HP:0000217 Xerostomia; HP:0001396 Fatigue; HP:0001382 Arthralgia; HP:0002664 Lymphoma (risk increased); HP:0006530 Interstitial lung disease; HP:0002093 Peripheral neuropathy (Heliyon, 2024; Clin Exp Rheumatol, 2024) (zhao2024acomprehensivereview pages 3-4, baldini2024pathogenesisofsjögrens pages 5-7).

Cell type involvement (CL terms) and evidence - CL: salivary gland epithelial cell; CL: plasmacytoid dendritic cell; CL: monocyte/macrophage; CL: T follicular helper cell; CL: CD8+ tissue-resident memory T cell; CL: B cell/plasma cell (Clin Exp Rheumatol, 2024; Front Immunol, 2024; Ann Rheum Dis, 2024) (baldini2024pathogenesisofsjögrens pages 5-7, qi2024advancesincellular pages 2-4, zhao2024acomprehensivereview pages 3-4).

Anatomical locations (UBERON terms) and evidence - UBERON:0001044 Salivary gland (labial, parotid); UBERON:0001811 Lacrimal gland (Heliyon, Sep 2024) (zhao2024acomprehensivereview pages 3-4).

Chemical entities (CHEBI) and evidence - CHEBI: class “Janus kinase inhibitor” (JAK inhibitor) — normalizes IFN–JAK–STAT activity ex vivo (Ann Rheum Dis, 2024) (zhao2024acomprehensivereview pages 3-4). - BAFF/APRIL inhibitors (biologic class) — rationale from glandular B-cell survival axis (Front Immunol, 2024) (qi2024advancesincellular pages 2-4).

Selected evidence items with URLs and publication dates - Gupta et al., Annals of the Rheumatic Diseases, Aug 2024: human gland and PBMC IFN–JAK–STAT activation corrected by JAK inhibitors; DOI: 10.1136/ard-2023-224842; URL: https://doi.org/10.1136/ard-2023-224842 (zhao2024acomprehensivereview pages 3-4). - Baldini et al., Clinical and Experimental Rheumatology, Nov 2024: one‑year pathogenesis review detailing epithelial IFN/LAMP3, cytotoxic CD8+ T-cell injury, TLS/lymphoma links; DOI: 10.55563/clinexprheumatol/i8iszc; URL: https://doi.org/10.55563/clinexprheumatol/i8iszc (baldini2024pathogenesisofsjögrens pages 5-7, baldini2024pathogenesisofsjögrens pages 3-4, baldini2024pathogenesisofsjögrens pages 2-3). - Qi et al., Frontiers in Immunology, Jul 2024: cellular/molecular pathways of salivary gland damage (TLRs, BAFF/APRIL, EMT/EMT, inflammasome); DOI: 10.3389/fimmu.2024.1405126; URL: https://doi.org/10.3389/fimmu.2024.1405126 (qi2024advancesincellular pages 2-4). - Chang et al., Arthritis Research & Therapy, Mar 2024: gland BCR repertoire features linked to clinical activity; DOI: 10.1186/s13075-024-03283-z; URL: https://doi.org/10.1186/s13075-024-03283-z (qi2024advancesincellular pages 2-4). - Song & Zhou, Clinical and Experimental Rheumatology, Sep 2024: TLR7 pathway in pSS; DOI: 10.55563/clinexprheumatol/cmmkod; URL: https://doi.org/10.55563/clinexprheumatol/cmmkod (qi2024advancesincellular pages 2-4). - He et al., multi-omics MR, May 2024: IFN–DNA methylation–cytokine interactions; URL: https://doi.org/10.21203/rs.3.rs-4371628/v1 (he2024interplayofinterferon pages 18-21). - Zhao et al., Heliyon, Sep 2024: genetics, signaling pathways, clinical course; DOI: 10.1016/j.heliyon.2024.e36220; URL: https://doi.org/10.1016/j.heliyon.2024.e36220 (zhao2024acomprehensivereview pages 3-4).

Embedded summary artifact | Category | Item (ontology / symbol) | Mechanistic role (1–2 lines) | Notes / applications | |---|---|---|---| | Innate cytokine signaling | Type I IFN — JAK-STAT (GO: type I interferon signaling pathway) | Amplifies ISG expression via JAK-STAT in epithelial & immune cells, driving chronic inflammation. | Biomarker (IFN signature); targetable with JAK inhibitors (normalises ISG expression). | | Pattern recognition receptors | TLR7 / TLR8 / TLR9 (GO: toll-like receptor signaling) | Endosomal sensing of ssRNA/DNA in pDCs/SGECs → MyD88-dependent type I IFN and proinflammatory cytokines. | Linked to autoantibody-driven activation; TLR7 gain-of-function associated with disease. | | Cytosolic DNA sensing | cGAS–STING (GO: cGAS-STING pathway) | Detects cytosolic DNA → TBK1/IRF3 activation and type I IFN production; implicated in SGEC stress responses. | Possible therapeutic target (STING inhibitors); connects metabolic/mitochondrial stress to IFN. | | B‑cell survival axis | BAFF / APRIL — TNFSF13B / TNFSF13; receptors TNFRSF13C (BAFF-R), TNFRSF13B (TACI), TNFRSF17 (BCMA) | Promotes B-cell survival, plasmablast/plasma cell maintenance and class switching in glands. | Rationale for BAFF/APRIL inhibitors (reduce autoantibodies, relapse after B-cell depletion). | | Helper T cells | T follicular helper (CL: Tfh cell) | Provide IL-21/IL-4 help to B cells, support ectopic GC formation and affinity maturation. | Tfh frequency correlates with autoantibody production; therapeutic interest (blockade of T–B interactions). | | Innate plasmacytoid cells | Plasmacytoid dendritic cell (CL: pDC) | Major source of IFN-α in response to nucleic-acid containing immune complexes, initiating IFN signature. | pDC-targeting strategies may dampen systemic IFN-driven pathology. | | Myeloid effectors | Monocytes / Macrophages (CL: monocyte, macrophage) | Produce IL-1β/TNF and chemokines (CCL3, CX3CL1) that recruit/activate lymphocytes and shape TLS formation. | Myeloid skewing linked to gland inflammation and fibrosis; potential biomarker axes. | | Cytotoxic residence | CD8+ tissue-resident memory T cell (CL: CD8+ Trm) | Local cytotoxicity (GZMB/GZMK, IFN-γ) causing acinar/ductal cell injury and loss of secretory cells. | CD103 blockade reduced gland damage in models — therapeutic proof-of-concept. | | Target tissue | Salivary gland epithelial cells (CL: salivary gland epithelial cell) | Active participants: antigen presentation (MHC II), PRR signaling, cytokine/chemokine secretion and IFN production. | SGECs drive local immune recruitment and may undergo EMT/ferroptosis; target for tissue-protective therapies. | | Adaptive receptor features | BCR repertoire alterations (concept) | Gland-infiltrating B cells show clonal expansion, somatic hypermutation and biased isotype/chain usage. | BCR features associate with clinical activity and lymphoma risk; useful for molecular stratification. | | Lymphoid architecture | Ectopic germinal centers / tertiary lymphoid structures (TLS) (concept) | Sites of local affinity maturation and long-lived plasma cell generation within glands. | TLS presence correlates with higher lymphoma risk; target for B-cell–directed interventions. | | Tissue remodeling | Fibrosis / EMT (GO: epithelial to mesenchymal transition) | Chronic inflammation induces TGF-β/SMAD-driven EMT and ECM deposition, leading to irreversible gland damage. | Explains progressive loss of function; antifibrotic strategies may preserve gland structure. | | Histopathology | Lymphoepithelial lesions (concept) | Epithelial hyperplasia with dense lymphoid infiltration, often pre-lymphomatous in parotid glands. | Clinicopathologic marker for severe gland involvement and lymphoma surveillance. | | Genetic susceptibility | IRF5, STAT4, HLA class II (HGNC: IRF5, STAT4, HLA-DQA1/HLA-DQB1) | Modulate innate IFN responses, antigen presentation and adaptive immunity; HLA associations stronger in anti-SSA+ cases. | Inform risk stratification and mechanistic subtyping; link to IFN-driven endotypes. | | Epigenetics | DNA hypomethylation of ISGs (concept) | Demethylation of IFN-regulated loci increases ISG expression in immune and epithelial cells. | Epigenetic markers correlate with severity; potential for biomarker/therapeutic epigenetic modulation. | | Chemokines / cytokines | CXCL13, CXCL10, IL21, BAFF (HGNC: CXCL13, CXCL10, IL21; TNFSF13B) | CXCL13/CXCL10 recruit B/T cells and drive TLS; IL-21 mediates Tfh help; BAFF sustains B cells. | Serum/tissue levels serve as activity biomarkers; targets for biologic therapies. | | Anatomy | Labial salivary gland; parotid salivary gland; lacrimal gland (UBERON: salivary gland, lacrimal gland) | Primary sites of lymphocytic infiltration, acinar loss and TLS formation leading to sicca symptoms. | Biopsy sites and imaging targets for diagnosis and spatial profiling. | | Therapeutics (small molecules / biologics) | JAK inhibitors (CHEBI: JAK inhibitor class); BAFF/APRIL inhibitors (drug class) | JAKi block IFN-JAK-STAT signaling in glands/PBMCs; BAFF/APRIL inhibitors reduce B-cell survival and autoantibody production. | Supported by ex vivo tissue studies and clinical trials; guide mechanism-based therapy selection. |

Table: Concise, citable map linking key pathways, cells, molecules and targets in primary Sjögren's syndrome pathogenesis; compiled from recent mechanistic reviews and multi-omic studies (qi2024advancesincellular pages 2-4, baldini2024pathogenesisofsjögrens pages 5-7, he2024interplayofinterferon pages 18-21).

Limitations and open questions - The precise initiating triggers (viral vs sterile nucleic-acid stress; epithelial metabolic/m6A defects) and their contribution across serostatus-defined subtypes remain under active investigation. The degree to which targeting epithelial-intrinsic PRR/IFN pathways (e.g., STING) alters long-term glandular outcomes is not yet established in clinical trials (Clin Exp Rheumatol, 2024; Ann Rheum Dis, 2024) (baldini2024pathogenesisofsjögrens pages 5-7, zhao2024acomprehensivereview pages 3-4).

Overall synthesis A coherent mechanistic model links epithelial PRR/IFN activation and JAK–STAT signaling to the recruitment and licensing of innate and adaptive immunity, with BAFF/APRIL and Tfh orchestrating TLS-dependent B-cell maturation and CD8+ Trm executing cytotoxic damage. Genetic/epigenetic predisposition tunes these responses, while chronic inflammation drives EMT/fibrosis and predisposes to lymphoma in a subset. These insights enable IFN- and B cell–targeted strategies and support molecular endotyping for precision therapy (Clin Exp Rheumatol, 2024; Ann Rheum Dis, 2024; Front Immunol, 2024) (baldini2024pathogenesisofsjögrens pages 5-7, zhao2024acomprehensivereview pages 3-4, qi2024advancesincellular pages 2-4).

References

  1. (zhao2024acomprehensivereview pages 3-4): Ting Zhao, Runrun Zhang, Zhaofu Li, Dongdong Qin, and Xinchang Wang. A comprehensive review of sjögren's syndrome: classification criteria, risk factors, and signaling pathways. Heliyon, 10:e36220, Sep 2024. URL: https://doi.org/10.1016/j.heliyon.2024.e36220, doi:10.1016/j.heliyon.2024.e36220. This article has 8 citations and is from a peer-reviewed journal.

  2. (baldini2024pathogenesisofsjögrens pages 5-7): Chiara Baldini, Loukas G. Chatzis, Giovanni Fulvio, Gaetano La Rocca, Elena Pontarini, and Michele Bombardieri. Pathogenesis of sjögren's disease: one year in review 2024. Clinical and experimental rheumatology, Nov 2024. URL: https://doi.org/10.55563/clinexprheumatol/i8iszc, doi:10.55563/clinexprheumatol/i8iszc. This article has 15 citations and is from a peer-reviewed journal.

  3. (baldini2024pathogenesisofsjögrens pages 3-4): Chiara Baldini, Loukas G. Chatzis, Giovanni Fulvio, Gaetano La Rocca, Elena Pontarini, and Michele Bombardieri. Pathogenesis of sjögren's disease: one year in review 2024. Clinical and experimental rheumatology, Nov 2024. URL: https://doi.org/10.55563/clinexprheumatol/i8iszc, doi:10.55563/clinexprheumatol/i8iszc. This article has 15 citations and is from a peer-reviewed journal.

  4. (baldini2024pathogenesisofsjögrens pages 2-3): Chiara Baldini, Loukas G. Chatzis, Giovanni Fulvio, Gaetano La Rocca, Elena Pontarini, and Michele Bombardieri. Pathogenesis of sjögren's disease: one year in review 2024. Clinical and experimental rheumatology, Nov 2024. URL: https://doi.org/10.55563/clinexprheumatol/i8iszc, doi:10.55563/clinexprheumatol/i8iszc. This article has 15 citations and is from a peer-reviewed journal.

  5. (qi2024advancesincellular pages 2-4): Wenxia Qi, Jiexiang Tian, Gang Wang, Yanfeng Yan, Tao Wang, Yong Wei, Zhandong Wang, Guohua Zhang, Yuanyuan Zhang, and Jia Wang. Advances in cellular and molecular pathways of salivary gland damage in sjögren’s syndrome. Frontiers in Immunology, Jul 2024. URL: https://doi.org/10.3389/fimmu.2024.1405126, doi:10.3389/fimmu.2024.1405126. This article has 13 citations and is from a peer-reviewed journal.

  6. (he2024interplayofinterferon pages 18-21): Jiale He, Fengtao Pang, Xueyan Shan, Ruihua Liu, Zilin Guo, Minlan Ye, Wenjing Liu, Kefei Yang, Xinyao Zhou, and Xiaopo Tang. Interplay of interferon signalling gene expression, dna methylation, and inflammatory cytokines in sjögren’s syndrome: a multi-omics mendelian randomization study. Unknown journal, May 2024. URL: https://doi.org/10.21203/rs.3.rs-4371628/v1, doi:10.21203/rs.3.rs-4371628/v1.